Karin Garvey
Karin’s background on both sides of the “v” enables her to devise effective strategies for her plaintiff clients and to address the pressures and concerns faced by defendants, leading to more resolutions and better results.
Karin’s background on both sides of the “v” enables her to devise effective strategies for her plaintiff clients and to address the pressures and concerns faced by defendants, leading to more resolutions and better results.
Karin E. Garvey is a partner in the New York office of DiCello Levitt and a member of the Antitrust and Competition practice group. With more than twenty-five years of litigation experience, Karin focuses on representing businesses and public pension funds in complex antitrust class actions.
Having spent 18 years on the defense side, Karin is uniquely able to deploy the knowledge she gained as defense counsel to the strategic advantage of her clients on the plaintiffs’ side. Karin brings significant experience to managing complex, multi-jurisdictional cases from initial case development through resolution and appeal and has engaged in all phases of trial preparation and trial and has briefed and argued appeals.
Karin has been appointed lead or co-lead counsel in multiple antitrust class actions, including Fusion Elite All Stars v. Varsity Brands, LLC (W.D. Tenn.) (representing a proposed class of direct purchasers in a case alleging monopolization and conspiracy to monopolize again the largest producer of All Star Cheerleading events and the sport’s governing body); In re Sensipar (Cinacalcet HCl) Antitrust Litigation (D. Del.) (representing a proposed class of indirect purchasers of the drug Sensipar in a case alleging that defendants conspired to delay the entry of generic competition for that drug); and In re Surescripts Antitrust Litigation (N.D. Ill.) (representing a proposed class of pharmacies who have charged the largest provider of e-prescription services of anticompetitive conduct). Karin was also appointed to the Plaintiff’s Steering Committee in In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal.) and In re Crop Inputs Antitrust Litigation (E.D. Mo.). Karin recently tried a case to verdict on behalf of the end-payor plaintiff class in In re Opana ER Antitrust Litigation (N.D. Ill.), playing a large role at the jury trial, including delivering significant portions of the plaintiffs’ opening statement and closing argument. While on the defense side, Karin led the defense of a branded pharmaceutical company in In re Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn.) up through a jury verdict in a pay-for-delay case.
Karin is recommended by Chambers & Partners USA, Band 2 for Antitrust Mainly Plaintiff in New York, and The Legal 500 for excellence in the antitrust practice. She has been described as “an experienced and thoughtful litigator. She has been in the trenches and knows how to work through complex issues.” She has also been recognized by Lawdragon as one of the “Leading Plaintiff Financial Lawyers in America.” Karin is regularly asked to participate on panels at class action and antitrust conferences, and she serves as an adjunct faculty member in the trial advocacy program at Northwestern University Pritzker School of Law.
